By increasing nitric oxide (NO) bioavailability, 1-MNA is directly related to the proper function of the endothelium. Impaired endothelial activity results in the development of many diseases such as cardiac diseases, vascular system diseases, gastrointestinal diseases, hepatic diseases and diabetes.
COVID-19 is an infectious respiratory tract disease caused by SARS-CoV-2. COVID-19 is not a brief infection, as it leads to a range of lasting consequences, such as chronic fatigue and exertional dyspnoea.
1-MNA at 58 mg/day improves exercise and fatigue tolerance in patients recovering from COVID-19 in just a month. Patients taking 1-MNA (58 mg/day) notice better physical performance and much more rarely feel extreme fatigue.
Studies have shown that 1-MNA reduces pulmonary fibrosis, lowers the level of eosinophils involved in the production of the factor that causes pulmonary fibrosis (TGF-β) and has anti-inflammatory effects by reducing the C-reactive protein level.
1-MNA influences blood vessel tension thereby reducing the risk of cardiovascular diseases, including atherosclerosis, arterial hypertension and chronic heart failure.
1-MNA through its effects on the secretory function of the vascular endothelium, contributes to lowering the level of proinflammatory cytokines and inflammatory markers, such as hsCRP and TNF-α. Proper levels of these markers contribute to the reduced the risk of diseases caused by inflammation.
1-MNA stimulates the secretion of endogenous prostacyclin (PGI2), which reduces platelet aggregation, thereby reducing the creation of blood clots in arteries.
Studies have demonstrated that 1-MNA reduces the amount of atherosclerotic plaque and reduces the level of cholesterol in blood, which together reduce the risk of atherosclerosis.
